Rita Nanda

17.0k total citations · 5 hit papers
205 papers, 6.3k citations indexed

About

Rita Nanda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Rita Nanda has authored 205 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Oncology, 78 papers in Pulmonary and Respiratory Medicine and 68 papers in Cancer Research. Recurrent topics in Rita Nanda's work include Advanced Breast Cancer Therapies (62 papers), HER2/EGFR in Cancer Research (49 papers) and Cancer Immunotherapy and Biomarkers (47 papers). Rita Nanda is often cited by papers focused on Advanced Breast Cancer Therapies (62 papers), HER2/EGFR in Cancer Research (49 papers) and Cancer Immunotherapy and Biomarkers (47 papers). Rita Nanda collaborates with scholars based in United States, United Kingdom and Spain. Rita Nanda's co-authors include Olufunmilayo I. Olopade, Charles M. Perou, Dominic T. Moore, Chad Livasy, Gamze Karaca, Maria Tretiakova, Peter Schmid, Dezheng Huo, Tatyana A. Grushko and Eric P. Winer and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Rita Nanda

189 papers receiving 6.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

2005 839 citations Rita Nanda, Olufunmilayo I. Olopade et al. profile →
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

2018 567 citations Sara M. Tolaney, Rita Nanda et al. profile →
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2018 460 citations Sylvia Adams, Sherene Loi et al. Annals of Oncology profile →
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

2018 348 citations Tiffany A. Traina, Kathy D. Miller et al. Journal of Clinical Oncology profile →
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database

2023 86 citations Fangyuan Zhao, Nan Chen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rita Nanda United States	34	4.3k	2.5k	1.5k	1.4k	1.1k	205	6.3k
Bjørn Naume Norway	45	3.4k 0.8×	3.1k 1.3×	2.5k 1.6×	1.1k 0.7×	862 0.8×	134	6.7k
Dongxia Gao Canada	27	2.9k 0.7×	2.4k 1.0×	1.5k 1.0×	761 0.5×	1.1k 1.0×	57	5.1k
Rinat Yerushalmi Israel	27	4.4k 1.0×	2.3k 0.9×	2.2k 1.4×	1.8k 1.2×	399 0.4×	119	6.7k
Priti Lal United States	34	3.0k 0.7×	2.0k 0.8×	2.5k 1.7×	2.4k 1.7×	1.3k 1.3×	128	6.7k
Mark Ayers United States	33	5.2k 1.2×	2.7k 1.1×	2.5k 1.6×	1.9k 1.3×	1.6k 1.5×	56	7.8k
Kunwei Shen China	37	2.7k 0.6×	2.2k 0.9×	1.6k 1.1×	914 0.6×	573 0.5×	231	5.2k
Aurelia Noske Germany	38	3.2k 0.7×	1.9k 0.8×	3.2k 2.1×	705 0.5×	950 0.9×	102	6.8k
Giampaolo Bianchini Italy	34	3.9k 0.9×	2.3k 0.9×	2.4k 1.6×	1.4k 0.9×	1.1k 1.0×	139	6.5k
Roberto Salgado Belgium	34	6.5k 1.5×	2.6k 1.1×	1.7k 1.1×	1.7k 1.2×	2.9k 2.8×	147	8.7k
Melinda L. Telli United States	37	3.4k 0.8×	1.7k 0.7×	1.8k 1.2×	1.2k 0.8×	527 0.5×	128	5.4k

Countries citing papers authored by Rita Nanda

Since Specialization

Citations

This map shows the geographic impact of Rita Nanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rita Nanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rita Nanda more than expected).

Fields of papers citing papers by Rita Nanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rita Nanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rita Nanda. The network helps show where Rita Nanda may publish in the future.

Co-authorship network of co-authors of Rita Nanda

This figure shows the co-authorship network connecting the top 25 collaborators of Rita Nanda. A scholar is included among the top collaborators of Rita Nanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rita Nanda. Rita Nanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Nan, Margarite D. Matossian, Murtuza Rampurwala, et al.. (2025). A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Research and Treatment. 211(1). 111–119. 1 indexed citations

Trivedi, Meghna S., Rebecca Shatsky, Rita Nanda, et al.. (2024). LBA15 Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) treatment strategy in the neoadjuvant setting: Results from the I-SPY 2.2 trial. Annals of Oncology. 35. S1208–S1209. 1 indexed citations

Hamilton, Erika, Rinath Jeselsohn, Sara A. Hurvitz, et al.. (2024). Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort. Cancer Research. 84(9_Supplement). PS15–3. 2 indexed citations

Thomas, Alexandra, Denise M. Wolf, Ronald Balassanian, et al.. (2024). Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.. Journal of Clinical Oncology. 42(23_suppl). 1–1. 1 indexed citations

Howard, Frederick M., Nan Chen, Olwen Hahn, et al.. (2024). Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. Journal of Oncology Pharmacy Practice. 3212339017–3212339017. 1 indexed citations

Meisel, Jane, Katia Khoury, A. Jo Chien, et al.. (2024). Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA509–LBA509. 4 indexed citations

Garrido-Castro, Ana C., Se Eun Kim, Rita Nanda, et al.. (2024). SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA1004–LBA1004. 20 indexed citations

Tung, Nadine, Mark E. Robson, Rita Nanda, et al.. (2024). TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.. Journal of Clinical Oncology. 42(16_suppl). 1021–1021. 8 indexed citations

Lin, Jing, Olga Karginova, Rita Nanda, et al.. (2024). Single-cell chemoproteomics identifies metastatic activity signatures in breast cancer. Science Advances. 10(43). eadp2622–eadp2622. 3 indexed citations

10.

Miyashita, Minoru, Joshua S. K. Bell, Stéphane Wenric, et al.. (2023). Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Research. 25(1). 12 indexed citations

11.

Hamilton, Erika, Hyo S. Han, Anne F. Schott, et al.. (2023). 390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial. Annals of Oncology. 34. S344–S344. 12 indexed citations

12.

Li, Wen, Natsuko Onishi, David C. Newitt, et al.. (2022). Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy. Cancers. 14(18). 4436–4436. 14 indexed citations

13.

Visvanathan, Kala, Leslie Cope, Mary Jo Fackler, et al.. (2022). Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. Clinical Cancer Research. 29(4). 784–790. 12 indexed citations

14.

Lehmann, Brian D., Vandana G. Abramson, Melinda E. Sanders, et al.. (2019). TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 26(9). 2111–2123. 113 indexed citations

15.

Nanda, Rita, Minetta C. Liu, Christina Yau, et al.. (2017). Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.. Journal of Clinical Oncology. 35(15_suppl). 506–506. 158 indexed citations

16.

Adams, Sylvia, Sherene Loi, Deborah Toppmeyer, et al.. (2017). Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.. Journal of Clinical Oncology. 35(15_suppl). 1088–1088. 55 indexed citations

17.

Paoletti, Costanza, Yufeng Li, Maria C. Muñiz, et al.. (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research. 21(12). 2771–2779. 75 indexed citations

18.

Abu‐Khalaf, Maysa, Ingrid A. Mayer, Andrew R. Allen, et al.. (2015). A phase 2, randomized, open-label study of lucitanib in patients with FGF aberrant metastatic breast cancer.. Journal of Clinical Oncology. 33. 2 indexed citations

19.

Santos, Jennifer F. De Los, Alan Cantor, Keith D. Amos, et al.. (2013). Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Cancer. 119(10). 1776–1783. 152 indexed citations

20.

Rimawi, Mothaffar F., Ingrid A. Mayer, Andres Forero, et al.. (2013). Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology. 31(14). 1726–1731. 187 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact